PDAC
Clinical trials for PDAC explained in plain language.
Never miss a new study
Get alerted when new PDAC trials appear
Sign up with your email to follow new studies for PDAC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets tough cancers in groundbreaking trial
Disease control Recruiting nowThis study is testing whether a new oral drug called TNG462 is safe and effective when combined with other cancer drugs for people with advanced pancreatic or non-small cell lung cancer. The trial will involve about 183 adults whose cancers have specific genetic changes (MTAP los…
Matched conditions: PDAC
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for pancreatic cancer patients in global drug trial
Disease control Recruiting nowThis study is testing whether a new drug called daraxonrasib, given alone or with standard chemotherapy, works better than chemotherapy alone for people with advanced pancreatic cancer that has spread. About 900 participants will be randomly assigned to receive one of three treat…
Matched conditions: PDAC
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Trial tests new drug duo against Tough-to-Treat cancer mutation
Disease control Recruiting nowThis study is testing a new combination of two drugs, IN10018 and RNK08954, for people with advanced solid tumors that have a specific genetic change called KRASG12D. The main goals are to find a safe and effective dose and to see if the treatment can shrink tumors. The study is …
Matched conditions: PDAC
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Breakthrough trial targets 'Undruggable' cancer mutations in pancreatic and colon tumors
Disease control Recruiting nowThis study is testing new targeted drugs called RAS inhibitors in combination with standard cancer treatments for people with advanced colorectal or pancreatic cancer. The goal is to find safe and effective doses while seeing if these new drug combinations can help control cancer…
Matched conditions: PDAC
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug trial targets 'Undruggable' cancer mutation
Disease control Recruiting nowThis early-stage study is testing a new drug called RMC-5127 in adults with advanced cancers that have a specific genetic change called KRAS G12V. The main goals are to find a safe dose and see how the body processes the drug, both when given alone and when combined with other ca…
Matched conditions: PDAC
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New drug combo targets 'Undruggable' cancer mutation in advanced patients
Disease control Recruiting nowThis study is testing whether combining the experimental drug GFH375 with either cetuximab or chemotherapy can help control advanced solid tumors that have a specific KRAS G12D mutation. The trial will enroll 126 adults whose cancers have progressed despite standard treatments. R…
Matched conditions: PDAC
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New hope to keep pancreatic cancer from returning after surgery
Disease control Recruiting nowThis study is testing whether a new oral drug, daraxonrasib, can help keep pancreatic cancer from coming back after surgery and chemotherapy. It will compare the drug to standard observation (no drug) in 500 patients who have had their tumor surgically removed and completed chemo…
Matched conditions: PDAC
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC
-
Massive 5,000-Person hunt for pancreatic Cancer's early warning signs
Knowledge-focused Recruiting nowThis study is creating a large registry of people at high risk for pancreatic cancer to help researchers find better ways to detect the disease early. It will collect blood samples, pancreatic fluid, and medical images from 5,000 participants over ten years. The goal is to use th…
Matched conditions: PDAC
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Mar 19, 2026 14:56 UTC